



Dr. Andrew Schiermeier is Chief Executive Officer of MEND (Medicine in Need). Prior to MEND, Dr. Schiermeier served as the CEO of Lantibio, Inc, a private development-stage biotech company with three late-stage compounds in respiratory and ophthalmology therapeutic areas. While at Lantibio, he was responsible for engineering the outlicensing of the company's lead compound to Alcon Research Labs, the world's leading ophthalmology company. Schiermeier also concurrently held the role of Vice President, Business Strategy & Valuation, and Head of Mergers & Acquisitions for a New York-based venture capital firm and merchant bank. While there, Schiermeier was instrumental in forming nearly a dozen private biotech companies in a broad range of therapeutic areas. Dr. Schiermeier has also spent more than a decade in various leadership roles building and/or contributing to the advisory services practices in pharmaceuticals and biotech within Ernst & Young, L.L.P. and Strategic Decisions Group. In those roles, he has led a variety of strategic initiatives, including dozens of product development strategies, some of the largest pharmaceutical industry mergers in history. He also served as Senior Director, and Global Head, of Portfolio Management for Aventis Pharmaceuticals.

Schiermeier holds a Ph.D. in Applied Mathematics from Harvard University, an M.S. in Biomechanical Engineering from Stanford University, a B.S. in Mechanical Engineering (Valedictorian) from Washington University in St. Louis, and an International MBA from College des Ingenieurs in Paris, France. He also speaks fluent French.